Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312351 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
A Phase 4 study, sponsored by Eyetech Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 262
- Enrollment target
NCT00312351: Clinical Trial Phase 4 study, sponsored by Eyetech Pharmaceuticals.
NCT00312351 is a Phase 4 study that was terminated before completion, run by Eyetech Pharmaceuticals. The registered enrollment target is 262 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00312351, a Phase 4 study, was terminated before completion, sponsored by Eyetech Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 262 participants
- Enrollment target
Study Summary
The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.
Interventions
- DRUG Pegaptanib sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Why NCT00312351 stopped before completion
NCT00312351 is an interventional study that assigns participants to a tested intervention. The registered 262 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 1 intervention - of which Pegaptanib sodium is the first listed.
NCT00312351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00312351 about?
NCT00312351 is a clinical study titled "A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)". The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cor...
What is the current status of trial NCT00312351?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 262 participants. The study started on 2006-04. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00312351?
The interventions under investigation include: Pegaptanib sodium (DRUG).
Who is sponsoring clinical trial NCT00312351?
This trial is sponsored by Eyetech Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00312351's enrollment target sits among peer trials
262 323rd of 2000 higher than 1,675 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
- NCT06293703 · 262 participants · NA
Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)
- NCT06780137 · 262 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia